Clinical Trial Update: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated brexpiprazole as an adjunctive treatment for adults with major depressive disorder in a school or work environment. The study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• REXULTI (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: MDD | Phase 3 | Status: COMPLETED | Results posted: 2016-03-29